Taglich Brothers Announces Investment Opinion: Taglich Brothers Starts American Biogenetic Sciences, Inc. (NasdaqSC: MABA) as Speculative Buy.Business Editors NOTE TO EDITORS: The following is an investment opinion issued by Taglich Brothers NEW YORK--(BUSINESS WIRE)--Nov. 7, 2000 Taglich Brothers, Inc. has initiated coverage on American Biogenetic bi·o·gen·e·sis also bi·og·e·ny n. 1. The principle that living organisms develop only from other living organisms and not from nonliving matter. 2. Generation of living organisms from other living organisms. 3. Sciences, Inc. (NasdaqSC: MABA MABA Massachusetts Association of Buyer Agents MABA Michigan Agri-Business Association (East Lansing, MI) MABA Madison Area Builders Association (Madison, Wisconsin) MABA Microplate Alamar Blue Assay ; recent price $1.56) with a speculative buy recommendation and a twelve to eighteen-month target price range of $6.25 to $6.75. For the six months ended June 30, 2000, revenues increased by 100% to $1.4 million versus $0.7 million for the same period last year, and gross margins increased to 80% versus 63% for the same period last year. For fiscal 2000, Taglich Brothers estimates that American Biogenetic Sciences will have revenues of $3.4 million, representing a 138% increase over 1999 levels, and a net loss of ($0.12) per share, representing an improvement over the loss of ($0.14) per share incurred in 1999. If it were not for the one-time non-cash preferred dividend preferred dividend n. a payment of a corporation's profits to holders of preferred shares of stock. (See: preferred stock) charge of $2.45 million that occurred during the first quarter, Taglich Brothers estimates that American Biogenetic Sciences would have had a net loss of ($0.06) per share for fiscal 2000. American Biogenetic Sciences, Inc., based in Copiague, New York Copiague (pronounced /KOH payg/) is a hamlet (and census-designated place) in Suffolk County, New York, United States. The population was 21,922 at the 2000 census. Once predominantly Italian-American, today Copiague is home to a large Polish-American population. , develops, commercializes, and markets neurological neurological, neurologic pertaining to or emanating from the nervous system or from neurology. neurological assessment evaluation of the health status of a patient with a nervous system disorder or dysfunction. pharmaceuticals, cardiovascular diagnostics, and monoclonal antibodies This is a list of monoclonal antibodies, antibodies which are clones of a single parent cell. When used as medications, the generic names end in -mab (see "Nomenclature of monoclonal antibodies"). . The Company has a promising pipeline of products under development and is also currently earning revenues through its Stellar Bio Systems, Inc. subsidiary, which manufactures immunodiagnostic immunodiagnostic pertaining to diagnosis by immune reactions. kits and reagents. Taglich Brothers, Inc., founded in 1992, is full-service broker Full-Service Broker A broker that provides a large variety of services to its clients, including research and advice, retirement planning, tax tips, and much more. Of course, this all comes at a price, as commissions at full-service brokerages are much higher than those at discount dealer focused exclusively on micro-cap companies. The Company defines the micro-cap segment of the equity market as companies with less than $250 million in market capitalization Market Capitalization A measure of a public company's size. Market capitalization is the total dollar value of all outstanding shares. It's calculated by multiplying the number of shares times the current market price. This term is often referred to as market cap. . Taglich Brothers, Inc. currently offers institutional brokerage services, investment banking for publicly traded micro-cap companies and comprehensive research coverage to the investment community. In December 1999, the Company launched its Website http://www.taglichbrothers.com to allow investors free access to its in depth research on micro-cap companies. Additional information is available upon request or on our website at http://www.taglichbrothers.com. The information and statistical data contained herein have been obtained from sources which we believe to be reliable but in no way are warranted by us as to accuracy or completeness. We do not undertake to advise you as to change in figures or our views. This is not a solicitation of any order to buy or sell. We, our affiliates, and any officer, director or stockholder, or any member of their families, may have a position in and may from time to time purchase or sell any of the above-mentioned or related securities. The Company mentioned in this report may from time to time be involved in an investment banking relationship with Taglich Brothers, Inc., or may pay a monthly fee for maintenance of our website. Details of any such relationship or compensation agreements are available upon request. The above statement is the opinion of Taglich Brothers, Inc. and is not a guarantee that the target price for the stock will be met or that predicted business results for the company will occur. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion